Latha Ramireddy1, William Tzu-Liang Chen2,3, Ching-Tien Peng1,4, Rouh-Mei Hu1, Tao-Wei Ke2, Hua-Che Chiang2, Sheng-Chi Chang2, Fuu-Jen Tsai4, Wan-Yu Lo5,6,7. 1. Department of Biomedical Informatics, Asia University, Taichung, Taiwan. 2. Division of Colorectal Surgery, Department of Surgery, China Medical University Hospital, Taichung, Taiwan. 3. College of Medicine, China Medical University, Taichung, Taiwan. 4. Department of Pediatrics, Children's Hospital, China Medical University, Taichung, Taiwan. 5. Department of Medical Research, China Medical University Hospital, Taichung, Taiwan. 6. Graduate Institute of Integrated Medicine, China Medical University, Taichung, Taiwan. 7. Department of Life Science, National Chung Hsing University, Taichung, Taiwan.
Abstract
BACKGROUND: Colorectal cancer (CRC) is the highest leading cause of cancer-related mortality in Taiwan. Macrophage migration inhibitory factor (MIF) has recently been defined as a novel protumorigenic factor that promotes cell proliferation, migration, and invasion. The aim of the present study is to identify the association between MIF gene polymorphism and CRC. METHODS: A case-control study was designed to test the hypothesis. A total of 192 biopsy-diagnosed CRC patients (CRC) and 256 healthy subjects (control) were recruited. Genotyping of four single nucleotide polymorphism (SNPs; rs755662, rs11548059, rs1049829, rs1803976) at chromosome positions 755662 (5' UTR), 11548059 (exon2), 1049829 (exon2), 1803976 (exon3) was performed using a Taqman SNP genotyping assay. RESULTS: There is a significant difference in genotype frequency distribution of rs755662 polymorphism between CRC patients and controls (P = 0.011). No significant difference was found in the frequency distribution of rs11548059, rs1049829, rs1803976 polymorphism in CRC patients and controls (P = 0.660, P = 0.700, and P = 0.959, respectively). Moreover, the MIF-173 SNP was also significantly associated with young patients (age < 50 years, P = 0.026) late stage (Stage IV, P = 0.038) and poor differentiation group (P = 0.040). Compared to the control group, the MIF-173 SNP also significantly associated with patients with stages III and IV (P = 0.034 and 0.003, respectively). CONCLUSION: The presence of MIF-173 (G/C) gene polymorphism (rs755662) was associated with susceptibility, patient age, and stages of CRC in Taiwanese.
BACKGROUND:Colorectal cancer (CRC) is the highest leading cause of cancer-related mortality in Taiwan. Macrophage migration inhibitory factor (MIF) has recently been defined as a novel protumorigenic factor that promotes cell proliferation, migration, and invasion. The aim of the present study is to identify the association between MIF gene polymorphism and CRC. METHODS: A case-control study was designed to test the hypothesis. A total of 192 biopsy-diagnosed CRC patients (CRC) and 256 healthy subjects (control) were recruited. Genotyping of four single nucleotide polymorphism (SNPs; rs755662, rs11548059, rs1049829, rs1803976) at chromosome positions 755662 (5' UTR), 11548059 (exon2), 1049829 (exon2), 1803976 (exon3) was performed using a Taqman SNP genotyping assay. RESULTS: There is a significant difference in genotype frequency distribution of rs755662 polymorphism between CRC patients and controls (P = 0.011). No significant difference was found in the frequency distribution of rs11548059, rs1049829, rs1803976 polymorphism in CRC patients and controls (P = 0.660, P = 0.700, and P = 0.959, respectively). Moreover, the MIF-173 SNP was also significantly associated with young patients (age < 50 years, P = 0.026) late stage (Stage IV, P = 0.038) and poor differentiation group (P = 0.040). Compared to the control group, the MIF-173 SNP also significantly associated with patients with stages III and IV (P = 0.034 and 0.003, respectively). CONCLUSION: The presence of MIF-173 (G/C) gene polymorphism (rs755662) was associated with susceptibility, patient age, and stages of CRC in Taiwanese.
Authors: A Kamimura; M Kamachi; J Nishihira; S Ogura; H Isobe; H Dosaka-Akita; A Ogata; M Shindoh; T Ohbuchi; Y Kawakami Journal: Cancer Date: 2000-07-15 Impact factor: 6.860
Authors: Leah B Sansbury; Andrew W Bergen; Kay L Wanke; Binbing Yu; Neil E Caporaso; Nilanjan Chatterjee; Luke Ratnasinghe; Arthur Schatzkin; Teresa A Lehman; Aravind Kalidindi; Ramakrishna Modali; Elaine Lanza Journal: Cancer Epidemiol Biomarkers Prev Date: 2006-03 Impact factor: 4.254
Authors: K L Meyer-Siegler; P L Vera; K A Iczkowski; C Bifulco; A Lee; P K Gregersen; L Leng; R Bucala Journal: Genes Immun Date: 2007-08-30 Impact factor: 2.676
Authors: Jun Nishihira; Teruo Ishibashi; Tsuyoshi Fukushima; Bailong Sun; Yuji Sato; Satoru Todo Journal: Ann N Y Acad Sci Date: 2003-05 Impact factor: 5.691
Authors: Ya-Yi Chang; Hildegard T Greinix; Anne M Dickinson; Daniel Wolff; Graham H Jackson; Reinhard Andreesen; Ernst Holler; Gerhard C Hildebrandt Journal: Cytokine Date: 2009-08-31 Impact factor: 3.861